Recent News

• 04.02.2025 - Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma
• 03.13.2025 - Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update
• 02.27.2025 - Alpha Tau to Participate in March Investor Conferences
• 02.24.2025 - Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification
• 02.03.2025 - Alpha Tau Announces FDA Approval of IDE Supplement to Expand Pilot Trial of Alpha DaRT® to Thirty Patients with Pancreatic Cancer in Two Cohorts, with Locally Advanced or Metastatic Disease
• 01.27.2025 - Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day
• 01.27.2025 - Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day

Recent Filings

• 04.02.2025 - EX-99.1 EX-99.1
• 04.02.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.12.2025 - 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
• 03.12.2025 - EX-99.1 EX-99.1
• 03.12.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 03.12.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.27.2025 - EX-99.1 EX-99.1
• 02.27.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.24.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.24.2025 - EX-99.1 EX-99.1